Repatha’s withdrawal from Denmark is best understood as an early signal of the impact of Most Favored Nation drug pricing ...
Amgen CEO Robert Bradway has declared 2026 a “springboard year” for the California big biotech, in which the growth of its ...
THOUSAND OAKS, Calif., Aug. 25, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has broadened the approved use of Repatha® (evolocumab) to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results